[{"address1": "2916 North Miami Avenue", "address2": "Suite 1000", "city": "Miami", "state": "FL", "zip": "33127", "country": "United States", "phone": "305 509 6897", "website": "https://verupharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company's development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.", "fullTimeEmployees": 189, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mitchell S. Steiner F.A.C.S., M.D.", "age": 62, "title": "Chairman, President & CEO", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 885324, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Harry  Fisch F.A.C.S., M.D.", "age": 64, "title": "Vice Chairman & Chief Corporate Officer", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michele  Greco", "age": 64, "title": "CFO & Chief Administrative Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 493703, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. K. Gary Barnette Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 676271, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Samuel  Fisch", "title": "Executive Director of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael J. Purvis", "title": "Executive VP, General Counsel & Corporate Strategy and Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kevin J. Gilbert CPA, J.D.", "title": "Executive Vice President of Corporate Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Martin  Tayler", "age": 54, "title": "Executive Vice President of FC2 Global Operations", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 180512, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip R. Greenberg J.D.", "title": "Executive VP & Deputy General Counsel", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Domingo  Rodriguez M.D.", "age": 61, "title": "Executive Vice President of Global Clinical Operations", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 10, "governanceEpochDate": 1714521600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.43, "open": 1.45, "dayLow": 1.3, "dayHigh": 1.48, "regularMarketPreviousClose": 1.43, "regularMarketOpen": 1.45, "regularMarketDayLow": 1.3, "regularMarketDayHigh": 1.48, "exDividendDate": 1398643200, "fiveYearAvgDividendYield": 3.71, "beta": -0.197, "forwardPE": -4.5666666, "volume": 2041361, "regularMarketVolume": 2041361, "averageVolume": 2527967, "averageVolume10days": 2706150, "averageDailyVolume10Day": 2706150, "bid": 1.34, "ask": 1.36, "bidSize": 800, "askSize": 100, "marketCap": 200541952, "fiftyTwoWeekLow": 0.36, "fiftyTwoWeekHigh": 1.92, "priceToSalesTrailing12Months": 12.589036, "fiftyDayAverage": 1.0052, "twoHundredDayAverage": 0.87295, "currency": "USD", "enterpriseValue": 212330656, "floatShares": 104404917, "sharesOutstanding": 146380992, "sharesShort": 11051921, "sharesShortPriorMonth": 9504183, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.075500004, "heldPercentInsiders": 0.14109, "heldPercentInstitutions": 0.46257, "shortRatio": 3.37, "shortPercentOfFloat": 0.0845, "bookValue": 0.353, "priceToBook": 3.88102, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -62719716, "trailingEps": -0.7, "forwardEps": -0.3, "pegRatio": -0.04, "enterpriseToRevenue": 13.329, "enterpriseToEbitda": -2.828, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "VERU", "underlyingSymbol": "VERU", "shortName": "Veru Inc.", "longName": "Veru Inc.", "firstTradeDateEpochUtc": 918743400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "89add2fa-4457-393d-9280-b0ed7e5dccbe", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.37, "targetHighPrice": 5.0, "targetLowPrice": 1.0, "targetMeanPrice": 3.0, "targetMedianPrice": 3.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 40579060, "totalCashPerShare": 0.277, "ebitda": -75073144, "totalDebt": 14308382, "quickRatio": 2.584, "currentRatio": 3.209, "totalRevenue": 15929890, "debtToEquity": 27.728, "revenuePerShare": 0.177, "returnOnAssets": -0.51093, "returnOnEquity": -1.2456601, "freeCashflow": -39926676, "operatingCashflow": -59500176, "revenueGrowth": -0.146, "grossMargins": 0.50310004, "operatingMargins": -4.11124, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-05-10"}]